I don’t want to discuss TLX valuation on these threads but assessment of over/ under valued would be subjective. With Clarity’s (Cu64) ascendence and TLX admitting limitations of Ga hence starting exploring Cu64 literally challenges future revenues from Illucix for PC if not for other conditions. This has to be considered in any TLX valuation IMO. The day our Cu64 gets FDA marketing approval, what would happen to Illucix revenues?
I don’t want to discuss TLX valuation on these threads but...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.04 |
Change
-1.100(15.4%) |
Mkt cap ! $1.934B | |||
| Open | High | Low | Value | Volume |
| $7.10 | $7.10 | $5.92 | $13.25M | 2.065M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 621 | $6.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.06 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |